Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA041081-02
Application #
3093823
Study Section
(SRC)
Project Start
1986-01-01
Project End
1990-12-31
Budget Start
1987-01-01
Budget End
1987-12-31
Support Year
2
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
Overall Medical
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Schindler, J; Sausville, E; Messmann, R et al. (2001) The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin Cancer Res 7:255-8
Schnell, R; Vitetta, E; Schindler, J et al. (2000) Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia 14:129-35
Schnell, R; Vitetta, E; Schindler, J et al. (1998) Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. Leuk Lymphoma 30:525-37
Senderowicz, A M; Vitetta, E; Headlee, D et al. (1997) Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann Intern Med 126:882-5
Baluna, R; Sausville, E A; Stone, M J et al. (1996) Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins. Clin Cancer Res 2:1705-12
Stone, M J; Sausville, E A; Fay, J W et al. (1996) A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 88:1188-97
Ghetie, M A; Podar, E M; Gordon, B E et al. (1996) Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma. Int J Cancer 68:93-6
Shen, G L; Li, J L; Vitetta, E S (1994) Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing. J Immunol 152:2368-76
Ghetie, M A; Picker, L J; Richardson, J A et al. (1994) Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood 83:1329-36
Amlot, P L; Stone, M J; Cunningham, D et al. (1993) A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82:2624-33

Showing the most recent 10 out of 40 publications